Renaissance Capital logo

BNTC News

Silenced: RNA biotech Silenseed withdraws $35 million IPO

Silenseed, a biotech developing RNA interference cancer drugs and delivery systems, withdrew its plans for an initial public offering on Tuesday. The company has first targeted pancreatic cancer for its combined RNA interference (RNAi) drug and delivery platform, which enables cancer therapies to be implemented directly into the core of solid tumors. Recent RNA biotechs Mirna...read more

US IPO Weekly Recap: One IPO and one bad week in the markets

Equity Selloff Hits Recent IPOs Recent IPOs have not been exempt from the steep selloff in the major indices. As of midday Friday, the Renaissance IPO Index was down 5.6% for the week, underperforming the S&P 500's -4.3% return. One of the most prominent IPOs of recent memory,...read more

Benitec Biopharma prices significantly downsized US IPO at $9.21

Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, raised $14 million by offering 1.5 million ADSs at $9.21. Each ADS was sold with one third of a warrant to purchase an ADS at a $5.50 exercise price. The company's ordinary shares trade on the Australian Stock Exchange under the ticker BLT. Benitec had originally planned to raise...read more

Microcap biotech Benitec Biopharma decreases proposed IPO deal size to $15 million

Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, reduced the number of ADSs it plans to offer for the second time and reduced the number of warrants offered.  The Balmain, Australia-based company now plans to raise $15 million by offering 2 million shares at a price of $10. The company had previously filed to offer 2...read more